Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29760214 | 0.93 | PDE4B (0.51) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL16269235 | 0.93 | PDE4B (0.51) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL21966679 | 0.86 | KDM4E (0.52) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL20744266 | 0.85 | MAPT (0.51) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL16271572 | 0.85 | KDM4E (0.51) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL15939963 | 0.84 | DDB1 (0.58) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL21381666 | 0.84 | HTT (0.53) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL15984969 | 0.84 | DDB1 (0.51) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL30149836 | 0.84 | HTT (0.53) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL23211935 | 0.83 | THRB (0.49) | KDM4EMAPTTHRBDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619406-A1 | TRICYCLIC COMPOUNDS | Schrödinger, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240307385-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-19 | — | — | US | disclosed |
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11969423-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| CN-111225910-B | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-3719019-B1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-01-19 | — | — | EP | disclosed |
| EP-3719019-B1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-01-19 | — | — | EP | disclosed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| EP-3719019-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-10-07 | — | — | EP | disclosed |
| WO-2014191336-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014191336-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| EP-1590326-A4 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | LUNDBECK & CO AS H (DK) | 2008-04-30 | — | — | EP | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-20060217418-A1 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2006-09-28 | — | — | US | disclosed |
| US-20060084649-A9 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2006-04-20 | — | — | US | disclosed |
| EP-1590326-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. Lundbeck A/S (DK) | 2005-11-02 | — | — | EP | disclosed |
| US-20040186103-A1 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-09-23 | — | — | US | disclosed |
| WO-2004064764-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. LUNDBECK A/S (DK) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307385-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | KDM4E 4291/4885MAPT 1598/4885THRB 1941/4885 |
| US-20060084649-A9 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | KDM4E 1703/4885MAPT 3026/4885THRB 409/4885 |
| US-11969423-B2 | Compounds | SDHA, SDHB, FDPS | KDM4E 4043/4885MAPT 881/4885THRB 2160/4885 |
| US-20060217418-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | KDM4E 1703/4885MAPT 3026/4885THRB 409/4885 |
| US-20040186103-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | KDM4E 1703/4885MAPT 3026/4885THRB 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.